There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on La Jolla Pharma (NASDAQ:LJPC), Mesoblast Ltd (NASDAQ:MESO) and Correvio Pharma Corp (NASDAQ:CORV) with bullish sentiments.
La Jolla Pharma (LJPC)
H.C. Wainwright analyst Edward White maintained a Buy rating on La Jolla Pharma today and set a price target of $48. The company’s shares closed yesterday at $15.23, close to its 52-week low of $14.65.
According to TipRanks.com, White is a 5-star analyst with an average return of 14.8% and a 45.3% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
La Jolla Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $58.75.
See today’s analyst top recommended stocks >>
Mesoblast Ltd (MESO)
H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Mesoblast Ltd today and set a price target of $17. The company’s shares closed yesterday at $6.29.
Kolbert noted:
“Our valuation is based on our therapeutic models and reflects our assumptions for the product launch dates, product attributes, and pricing, to determine the future revenue streams. We have not yet factored in China.”
According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.0% and a 36.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.
Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $18, representing a 186.2% upside. In a report issued on October 12, Maxim Group also maintained a Buy rating on the stock with a $16 price target.
.
Correvio Pharma Corp (CORV)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Correvio Pharma Corp today and set a price target of $10.50. The company’s shares closed yesterday at $3.74.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.5% and a 34.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Tyme Technologies Inc.
Correvio Pharma Corp has an analyst consensus of Strong Buy, with a price target consensus of $7.10, representing an 89.8% upside. In a report issued on October 12, Mackie Research also upgraded the stock to Buy with a $4.70 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
